Ozempic, Wegovy Weight-Loss Drugmaker On Long-Term Effects

Опубликовано: 08 Июнь 2024
на канале: Bloomberg Television

5,531

#Ozempic #Wegovy #obesity #diabetes #weightloss #healthcare #pharmaceuticals #novonordisk #drugs #leadership #CEO

Novo Nordisk’s blockbuster diabetes and obesity drugs, Ozempic and Wegovy, are revolutionizing the weight loss industry. Both contain the key ingredient, semaglutide - generating billions in sales. In some cases, patients might need to take the drugs indefinitely to avoid regaining much of the weight they lost. Speaking on Bloomberg’s Leaders With Lacqua, Novo Nordisk CEO Lars Fruergaard Jørgensen gives his personal views on the prospects of lifelong treatment and why the company will need to build a portfolio of interventions.

Watch the full interview:    • The CEO Behind Ozempic, Wegovy and Eu...

#bloomberg #leaderswithlacqua #francinelacqua
--------
More on Bloomberg Television and Markets

Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9
Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more.

Connect with Bloomberg Television on:
X:   / bloombergtv
Facebook:   / bloombergtelevision
Instagram:   / bloombergtv

Connect with Bloomberg Business on:
X:   / business
Facebook:   / bloombergbusiness
Instagram:   / bloombergbusiness
TikTok: https://www.tiktok.com/@bloombergbusi...
Reddit:   / bloomberg
LinkedIn:   / bloomberg-news

More from Bloomberg:
Bloomberg Radio:   / bloombergradio

Bloomberg Surveillance:   / bsurveillance
Bloomberg Politics:   / bpolitics
Bloomberg Originals:   / bbgoriginals

Watch more on YouTube:
Bloomberg Technology:    / @bloombergtechnology
Bloomberg Originals:    / @business
Bloomberg Quicktake:    / @bloombergquicktake
Bloomberg Espanol:    / @bloomberg_espanol
Bloomberg Podcasts:    / @bloombergpodcasts